

## Characterising the selectivity of ER $\alpha$ -glucosidase inhibitors

### Supplementary Data: Figures S1-S6 and Table SI

**Figure S1** *The effects of active compounds are independent of glycoprotein substrate*

**Figure S2** *Migration profiles of glycoprotein species generated by active compounds*


**Table SI** *Mass spectrometric analysis of GII $\alpha$  (*C. thermophilum*)*

**Figure S3** *Active compounds are competitive inhibitors of ER  $\alpha$ -glucosidase II*

**Figure S4**  *$K_i$  calculations for ER  $\alpha$ -glucosidase II inhibitors*


**Figure S5** *Alignment of ER  $\alpha$ -glucosidase II  $\alpha$ -subunit sequences*

**Figure S6** *Bonding between active inhibitors and residue D<sub>640</sub> of mouse GII $\alpha$*



**Figure S1. The effects of active compounds are independent of glycoprotein substrate.** Protein substrates were synthesised in the presence, or absence, of the compounds indicated (5 mM) using the co-translational system as described in the

legend to Figure 3 (see main text) and radiolabelled products analysed by SDS-PAGE. Substrates examined were: (**Ai, Aii**) OPG1Kcv; potassium channel protein Kcv modified with an N-terminal reporter containing one N-glycosylation site (residues 1-26 of bovine rhodopsin, residue T4 mutated to A) and two transmembrane domains (TM1 and TM2), (**Aiii, Aiv**) OPG2Kcv, potassium channel protein Kcv modified with an N-terminal reporter with both N-glycosylation sites intact (Watson et al. 2013), (**Bi, Bii**) ppcecAOPG1, preprocecropin A modified with a C-terminal reporter (a 14 residue N-terminal fragment of bovine rhodopsin) containing one N-glycosylation site (Johnson et al. 2012), (**Biii, Biv**) ppcecAOPG2 (cf. Figure 3B), preprocecropin A modified with a C-terminal reporter (residues 1-18 of bovine rhodopsin) containing two N-glycosylation sites, (**Ci, Cii**) pp $\alpha$ F, the yeast secretory protein prepro-alpha-factor comprised of a signal sequence and three endogenous sites for N-glycosylation (N23, N57 and N67); nc, non-cleaved signal sequence forms of ppcecAOPG1, ppcecAOPG2 or pp $\alpha$ F; sc, signal cleaved forms.




**Figure S2. Migration profiles of glycoprotein species generated by active compounds.** The gel shifts of the N-glycosylated species of (A) OPG2Kcv, (B) ppcecAOPG2 and (C) prepro-alpha-factor (ppαF) in Supplementary Figure S1 (see Aiv, Biv, Cii lanes 1, 2, 3, 4, 5, 6 and 10) were analysed as described in the legend to Figure 3 (see main text). Migration profiles were generated using the doubly N-glycosylated species with the exception of ppαF as the 1-3 Gly forms were not distinctly distinguishable from each other.  $\Delta$ Gly depicts alterations in N-glycan trimming as judged by changes in glycoprotein mobility, with the G3M9 N-glycan form (based on CST treatment) denoted by an asterisk (\*).

**Table S1. Mass spectrometric analysis of GII $\alpha$  (*C. thermophilum*)**

Identified Proteins	Unique Peptides	Total Spectra	Sequence Coverage (%)	Mw (kDa)
<sup>a</sup> GII $\alpha$ : OS= <i>C. thermophilum</i> GN=CTHT_0064960 PE=1 SV=1	89	1247	78	111
<sup>a</sup> Serum albumin: OS= <i>Bos taurus</i> GN=ALB PE=1 SV=4	3	3	6	69
<sup>b</sup> 2-oxoglutarate dehydrogenase decarboxylase component: OS= <i>E. coli</i> D6-113.11 GN=sucA PE=4 SV=1	9	10	13	105
<sup>b</sup> Aconitate hydratase B: OS= <i>E. coli</i> 1-176-05_S3_C2 GN=acnB PE=3 SV=1	4	4	6	91
<sup>b</sup> Valine--tRNA ligase: OS= <i>E. coli</i> GN=valS PE=3 SV=1	5	5	6	108
<sup>b</sup> Aconitate hydratase: OS= <i>E. coli</i> 1-176-05_S3_C2 GN=acnA PE=3 SV=1	3	3	3	98


<sup>a</sup> Database: BiOMS, University of Manchester, <sup>b</sup> Database: Swissprot and Trembl;

Protein Threshold: 95%; Minimum number of Peptides: 2; Peptide Threshold: 50%; Identified proteins are named according to the FASTA format wherein: OS = organism name, GN = gene name, PE = protein existence, SV = sequence version.



**Figure S3. Active compounds are competitive inhibitors of ER  $\alpha$ -glucosidase II.**

PNPG (2 mM, 1.5 mM, 1 mM, 500  $\mu\text{M}$ , 350  $\mu\text{M}$ , 200  $\mu\text{M}$ , 150  $\mu\text{M}$ , 125  $\mu\text{M}$ , 100  $\mu\text{M}$  and 75  $\mu\text{M}$ ) and inhibitor, at varying concentrations as indicated, were incubated with GlI $\alpha$  (6  $\mu\text{g}/\text{mL}$ ) at 37°C and absorbance measurements ( $\lambda = 410 \text{ nm}$ , 1 min intervals, 90 min) used to generate Lineweaver-Burk plots for (A) CST, (B) DAB, (C) DMDP, (D), CSU. Enzyme activity assays were performed in triplicate ( $n=3$ ). CST, DAB, DMDP and CSU competitively inhibit ER  $\alpha$ -glucosidase II.




**Figure S4.  $K_i$  calculations for ER  $\alpha$ -glucosidase II inhibitors.**

The data from the experiments described in the legend to Supplementary Figure S3, together with the values for concentrations of DAB greater than 6.25  $\mu\text{M}$  that were not included in Supplementary Figure S3B, were used to generate substrate-velocity curves ( $n=3$ ) and  $K_i$  values estimated using the Michaelis-Menten model for competitive inhibition. The resulting values were (A) CST;  $K_i$   $2.60 \pm 0.58 \mu\text{M}$ ,  $V_{\text{MAX}}$   $74.72 \pm 1.83 \mu\text{M/s}$ ,  $K_M$   $192.8 \pm 14.12 \mu\text{M}$ ,  $R^2 = 0.982$ , (B) DAB;  $K_i$   $0.187 \pm 0.003 \mu\text{M}$ ,  $V_{\text{MAX}}$   $64.61 \pm 0.82 \mu\text{M/s}$ ,  $K_M$   $179.4 \pm 7.43 \mu\text{M}$ ,  $R^2 = 0.991$ , (C) DMDP;  $K_i$   $18.07 \pm 0.51 \mu\text{M}$ ,  $V_{\text{MAX}}$   $62.98 \pm 1.1 \mu\text{M/s}$ ,  $K_M$   $171.4 \pm 10.12 \mu\text{M}$ ,  $R^2 = 0.973$ , (D) CSU;  $K_i$   $4.07 \pm 0.06 \mu\text{M}$ ,  $V_{\text{MAX}}$   $69.35 \pm 0.89 \mu\text{M/s}$ ,  $K_M$   $189.3 \pm 7.77 \mu\text{M}$ ,  $R^2 = 0.991$ . Data was fitted using  $V_{\text{MAX}}$  and  $K_M$  values obtained from non-inhibitor controls measured at the same time as inhibitor samples for each compound.





implicated in forming in ionic interactions are indicated by asterisks (\*) whilst residue H698 implicated in hydrogen bonding is indicated by a filled circle (●). These residues are given according to numbering of the murine sequence and are discussed in the main text.



**Figure S6. Bonding between active inhibitors and residue D<sub>640</sub> of mouse GII $\alpha$ .**

The estimated distance between the endocyclic nitrogen of the four active inhibitors and residue D<sub>640</sub> of murine GII $\alpha$  was calculated by *in silico* modelling (see materials and methods). In the case of DAB (**A**) the calculated distance is short enough to potentially form an ionic interaction (purple dashed line). For the other three compounds studied, DMDP (**B**), CST (**C**) and CSU (**D**), their endocyclic nitrogen atoms are located further away from residue D<sub>640</sub> thereby precluding any ionic interaction (black dashed lines).